Clinical

Abnormal exercise EKG in the setting of normal stress echo linked with increased CV risk


 

Background: Exercise EKG is often integrated with stress echocardiography, but discordance with +EKG/–Echo has unknown significance.

Study design: Observational cohort study.

Setting: Duke University Medical Center, Durham, N.C.

Synopsis: 47,944 patients without known coronary artery disease underwent exercise stress echocardiogram (Echo) with stress EKG. Of those patients, 8.5% had +EKG/–Echo results, which was associated with annualized event rate of adverse cardiac events of 1.72%, which is higher than the 0.89% of patients with –EKG/–Echo results. This was most significant for composite major adverse cardiovascular events less than 30 days out, with an adjusted hazard ratio of 8.06 (95% confidence interval, 5.02-12.94). For major adverse cardiovascular events greater than 30 days out, HR was 1.25 (95% CI 1.02-1.53).

Bottom line: Patients with +EKG/–Echo findings appear to be at higher risk of adverse cardiac events, especially in the short term.

Citation: Daubert MA et al. Implications of abnormal exercise electrocardiography with normal stress echocardiography. JAMA Intern Med. 2020 Jan 27. doi: 10.1001/jamainternmed.2019.6958.

Dr. Ho is a hospitalist and associate professor of medicine at University of Texas Health, San Antonio.

Recommended Reading

Medication in heart failure: Pro tips on therapy with the ‘four pillars of survival’
The Hospitalist
First risk score to predict bleeding risk after TAVR
The Hospitalist
Are left atrial thrombi that defy preprocedure anticoagulation predictable?
The Hospitalist
Simple risk assessment predicts post-PCI ischemic events
The Hospitalist
AHA: Don’t delay COVID shot while CDC reviews myocarditis cases
The Hospitalist
Reversal agents curb DOAC-related bleeding but deaths still high
The Hospitalist
U.S., international MIS-C studies yield disparate results
The Hospitalist
Prophylactic anticoagulation tied to lower death rate in COVID
The Hospitalist
Sotagliflozin use in T2D patients linked with posthospitalization benefits in analysis
The Hospitalist
FDA to add myocarditis warning to mRNA COVID-19 vaccines
The Hospitalist
   Comments ()